Annual report pursuant to Section 13 and 15(d)

Statement of Changes in Stockholders' Equity

v3.21.1
Statement of Changes in Stockholders' Equity - 6 months ended Dec. 31, 2020 - USD ($)
Additional Paid-in Capital
Accumulated Deficit
Class A Common Stock
Class B Common Stock
Total
Balance at the beginning at Jun. 23, 2020 $ 0 $ 0 $ 0 $ 0 $ 0
Balance at the beginning (in shares) at Jun. 23, 2020     0 0  
Common shares issued to initial shareholder 29,406     $ 594 30,000
Common shares issued to initial shareholder (in shares)       5,943,750  
Sale of 23,775,000 units at $10 per unit in IPO, including over-allotment, net of underwriters' discount and offering expenses 236,139,594   $ 2,378   236,141,972
Sale of 23,775,000 units at $10 per unit in IPO, including over-allotment, net of underwriters' discount and offering expenses (in shares)     23,775,000    
Sale of 462,500 units at $10 per unit in private placement 4,624,954   $ 46   4,625,000
Sale of 462,500 units at $10 per unit in private placement (in shares)     462,500    
Sale of 3,848,750 $11.50 exercise price warrants at $1.00 per warrant in private placement 3,848,750       3,848,750
Sale of 1,512,500 $15.00 exercise price warrants at $0.10 per warrant in private placement 151,250       151,250
Issuance of underwriter units, including over-allotment (11)   $ 11    
Issuance of underwriter units, including over-allotment (in shares)     118,875    
Common shares subject to possible redemption (217,173,101)   $ (2,121)   (217,175,222)
Common shares subject to possible redemption (in shares)     (21,215,577)    
Classification of warrants as liabilities at issuance (14,583,290)       (14,583,290)
Net loss   (8,038,450)     (8,038,450)
Balance at the ending at Dec. 31, 2020 $ 13,037,552 $ (8,038,450) $ 314 $ 594 $ 5,000,010
Balance at the ending (in shares) at Dec. 31, 2020     3,140,798 5,943,750